Medication Description: Phenyl Salicylate (Phenylii salicylas)
Phenylsalicylate (Phenylii salicylas).
Phenyl ester salicylic acid.
Synonyms: Salol, Phenylium salicylicum, Salolum.
White crystalline powder or small, colorless crystals with a faint odor. Practically insoluble in water, soluble (1:10) in alcohol, solutions of caustic alkalis.
Phenyl salicylate (salol) was synthesized long ago (1886, L. Nentsky) with the aim of creating a drug that would not disintegrate in the acidic contents of the stomach and did not act irritatingly on the gastric mucosa, and if it was split in the alkaline contents of the intestine, it would release salicylic acid and phenol. Phenol would have a depressing effect on the pathogenic microflora of the intestine, salicylic acid would have some antipyretic and anti-inflammatory effect, and both compounds, partially released from the body by the kidneys, would disinfect the urinary tract.
This principle (the "salovy" principle - the Nentsky principle) was essentially one of the first experiments to create prodrugs (see also Hexamethylenetetramine).
For a long time, phenyl salicylate has been widely used in intestinal diseases (colitis, enterocolitis), in cystitis, pyelitis, pyelonephritis.
Compared with modern antibacterial drugs: antibiotics, sulfonamides, fluoroquinolones, etc. - phenyl salicylate is much less active. However, it has low toxicity, does not cause dysbacteriosis and other complications and therefore continues to sometimes be used in outpatient practice (often in combination with other drugs) for milder forms of these diseases. For more severe forms of the disease, it is necessary to use more active drugs.
Phenyl salicylate is administered orally at 0.25 - 0.5 g per reception, 3-4 times a day, often in combination with antispasmodic binders and other means.
Product form: powder, tablets of 0.25 and 0.5 g and various combined tablets: a) tablets <Bezalol> (Tabulettae <Besalolum>); composition: phenyl salicylate 0.3 g, belladonna extract 0.01 g; b) <Urobesal> tablets (Tabulettae << Urobesalum >>); composition: phenyl salicylate and heximethylentetramine 0.25 g, beauty extract, 0,015 g; c) << Tansal >> tablets (Tabulettae <Tansalum>); composition: phenyl salicylate and tanalbine 0.3 g each; g) phenylsalicylate and bismuth nitrate of the main, of 0.25 g each, of belladonna extract 0.015 g.
Phencortosolum. Contains phenyl salicylate and hydrocortisone acetate. It is used as a photoprotective and anti-inflammatory agent for photodermatosis, discoid lupus erythematosus. The course of treatment is 7 to 10 days. If necessary, repeat the treatment after 5 to 7 days.
Product: emulsion in aerosol cans with a capacity of 55 g.
When pressing the cylinder valve for 1 to 2 seconds, 7–14 cm of foam (0.7–1.4 g of foam) is sufficient to cover 500 from the skin surface. Simultaneously, you can apply to the skin up to 30 cm 'foam. The foam is evenly rubbed into the skin with massaging movements.
Do not use the drug on sunny days of the cold season.
Storage: at a temperature not higher than 40 C.